2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.842

Change

-0.02 (-0.29)%

Market Cap

USD 0.52B

Volume

900.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-08 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.36 (-1.38%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.72 (-1.42%)

USD 116.66B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.69 (-1.27%)

USD 91.05B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.34 (+0.07%)

USD 85.22B
FRCJ:F UBS MSCI Japan Socially Respon..

-0.31 (-1.45%)

USD 74.74B
EUNL:F iShares Core MSCI World UCITS ..

-0.06 (-0.06%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-3.05 (-1.34%)

USD 55.89B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.20 (-1.31%)

USD 55.84B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.04 (-0.05%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.01 (+0.01%)

USD 51.63B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.53% 41% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.53% 38% F 47% F
Trailing 12 Months  
Capital Gain 4.83% 44% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.83% 42% F 50% F
Trailing 5 Years  
Capital Gain 40.31% 61% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.31% 61% D- 51% F
Average Annual (5 Year Horizon)  
Capital Gain 6.68% 71% C- 69% C-
Dividend Return 6.68% 70% C- 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.79% 39% F 70% C-
Risk Adjusted Return 45.16% 68% D+ 73% C
Market Capitalization 0.52B 62% D 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.